Relation between immuno-reacton and effectiveness of DFPP among the chronic hepatitis C patients with PEG-IFN and RBV combination therapy.

Relation between immuno-reacton and effectiveness of DFPP among the chronic hepatitis C patients with PEG-IFN and RBV combination therapy. - Immuno-reaction and effectiveness of DFPP therapy

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000002326

Enrollment

Registered

2009-08-20

Start date

2009-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic hepatitis C

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Chornic hepatitis C patients who can recive PEG-IFN, RBV and DFPP combination therapy

Exclusion criteria

Exclusion criteria: The existence of the other type of liver diseases.

Design outcomes

Primary

Measure	Time frame
We evalulate the immunological parameter before and after DFPP therapy.	—

Countries

Japan

Contacts

Public ContactYasuteru Kondo

Tohoku University Hospital Gastroenterology

yasuteru@ebony.plala.or.jp022-717-7171

Outcome results